Mitochondrial dysfunction research transforms mental health: Dr. Ana Andreazza's vision

University of Toronto professor shares insights on metabolic psychiatry breakthroughs in exclusive Genomic Press Interview series

2024-11-07

(Press-News.org) Toronto, Canada, 7 November 2024 – From a curious young scientist investigating her grandfather's family wine to a leading expert in mitochondrial health and mental illness, Dr. Ana Cristina Andreazza's journey exemplifies the power of personal motivation in driving scientific innovation. As founder and Scientific Director of the Mitochondrial Innovation Initiative (Mito2i), Dr. Andreazza is revolutionizing our understanding of the connection between cellular energy production and mental health.

In an illuminating Genomic Press Interview, published in Brain Medicine on November 7, 2024, Dr. Andreazza shares how family experiences shaped her pioneering research. "My father, a brilliant mathematician and professor of statistics, possessed an insatiable curiosity but struggled with untreated metabolic psychiatric issues," Dr. Andreazza reveals. "His journey fueled my commitment to identifying biomarkers that could demystify and reduce the stigma surrounding such conditions."

Her current research spans three transformative areas: the role of mitochondrial dysfunction in mood disorders, enhancing mitochondrial health in organ transplantation, and developing innovative mitochondrial transplantation techniques. A defining moment came in 2014 when a mother's question about the connection between bipolar disorder and mitochondrial disease sparked a new research direction.

"My goal is to identify biomarkers that can pave the way for personalized treatments in metabolic psychiatry," Dr. Andreazza explains. Her team's work on brain organoids derived from patient stem cells has revealed crucial insights into how mitochondrial impairments affect mood disorders, potentially opening new therapeutic pathways.

The interview highlights Dr. Andreazza's innovative approach to mitochondrial transplantation, utilizing biomaterials to encapsulate mitochondria for regenerative therapy. This groundbreaking work raises intriguing questions about the future of personalized medicine: Could mitochondrial therapy revolutionize treatment for both psychiatric and metabolic disorders? How might stable mitochondrial transplantation transform regenerative medicine?

As holder of a Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders, Dr. Andreazza emphasizes the importance of collaborative science and diverse perspectives. Her work bridges multiple disciplines, from neuropsychiatry to organ transplantation, creating unprecedented opportunities for cross-disciplinary innovation.

Dr. Andreazza's Genomic Press interview is part of a larger series that highlights the people behind today’s most influential scientific ideas. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that delve into the scientist’s impact on the field, while also touching on broader human themes. More information on the research leaders and research rising stars featured by Genomic Press can be found in our website: https://genomicpress.com.

The full Genomic Press Interview, titled “Ana Cristina Andreazza: Driven by curiosity – transforming mental health through mitochondrial innovation” is available on 7 November 2024 in Brain Medicine, providing detailed insights into Dr. Andreazza’s research methodology and vision for the future of metabolic psychiatry. The interview is freely available online at [[url to come]].

About Brain Medicine: Brain Medicine (ISSN: 2997-2639) is a peer-reviewed journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal’s scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.

END

[Attachments] See images for this press release:

ELSE PRESS RELEASES FROM THIS DATE:

Dr. Nora Volkow shares insights on addiction science and harm reduction in Genomic Press interview

2024-11-07

Bethesda, Maryland, USA, 7 November 2024 – Dr. Nora Volkow's mission to revolutionize addiction treatment began with a deeply personal observation: watching how excessive substance use could profoundly alter a person’s behavior while simultaneously triggering social rejection by others. As the first woman and Hispanic Director of the National Institutes of Health’s National Institute on Drug Abuse (NIDA), Dr. Volkow has dedicated her career to investigating how drugs affect the human brain and how these disruptions contribute to the behavioral/emotional ...

25-year study reveals key factors in healthy brain aging and cognitive performance

2024-11-07

Edinburgh, Scotland, 7 November 2024 – A groundbreaking 25-year research program has unveiled key insights into how our brains age and what factors influence cognitive performance throughout life. The findings, published on 7 November 2024 in Genomic Psychiatry, draw from the Lothian Birth Cohorts (LBC) studies, which uniquely tracked participants' cognitive abilities from childhood through their eighth decade of life. Professor Ian Deary and Dr. Simon Cox from the University of Edinburgh present remarkable discoveries that challenge conventional wisdom about brain aging. Their research ...

First clinical trial reveals promise of psilocybin treatment for anorexia nervosa

2024-11-07

San Diego, California, 7 November 2024 – In a groundbreaking exploration of psychedelic medicine's potential for treating one of psychiatry's most challenging conditions, researchers at University of California, San Diego (UCSD) provided an analysis and further details of a trial published in Nature Medicine (https://pmc.ncbi.nlm.nih.gov/articles/PMC10427429/) that had shown how psilocybin therapy affects individuals with anorexia nervosa. In the new peer-reviewed Emerging Topic article in Psychedelics ...

Fabrication of 4-inch wafer-scale heterostructure via PECVD drives AI semiconductor performance innovation!

2024-11-07

As artificial intelligence (AI) technology advances, the demand for higher-performing semiconductors is rapidly growing. The development of new materials and innovative structures to achieve high-performance semiconductors has become crucial. For the first time globally, a 4-inch heterostructure fabrication technology using plasma-enhanced chemical vapor deposition (PECVD) has been developed. This breakthrough enables the production of low-power, high-performance semiconductors, surpassing the capabilities of traditional silicon-based technology. The research team led by Senior Researcher Hyeong-U Kim of the Semiconductor Manufacturing Research Center of the ...

Plastic device aids robot-assisted heart surgery

2024-11-07

Robot-assisted heart surgery usually requires an assistant at the operating table to help the surgeon insert the robot arm through a small incision. The assistant has to constantly make sure the surgeon has enough room to operate via the robot arm. For greater independence on the surgeon’s side, an Osaka Metropolitan University-led group has developed a device that can secure the surgical field. Graduate School of Medicine Professor Toshihiko Shibata and Associate Professor Yosuke Takahashi worked with colleagues and small and ...

UVM scientists find space-for-time substitutions exaggerate urban bird–habitat ecological relationships

2024-11-07

As bird populations dwindle across the globe, a new study from University of Vermont researchers suggests some species may be more flexible to habitat changes than previously understood, creating new opportunities for supporting populations through city planting efforts. The team’s findings were published in the Journal of Animal Ecology today. While studies have found bird populations are on the decline—Canada and the United States have lost nearly three billion birds over the last half century—measuring ...

Molecular Frontiers Symposium in Hong Kong “Frontiers of New Knowledge in Science”

2024-11-07

Event Date: 15 November 2024 to 17 November 2024 Time: 9:00am - 6:30pm Venue: Main Hall, Shaw Auditorium, HKUST INTRODUCTION The Molecular Frontiers Symposium, organized by the globally renowned Molecular Frontiers Foundation - founded by the Royal Swedish Academy of Sciences - is recognized as one of the most influential scientific organizations worldwide. For the first time in the organization’s history, the Foundation's annual flagship symposium will be held in Greater China, hosted at The Hong Kong University of Science and Technology. With the theme "Frontiers of New Knowledge in Science", the Symposium ...

Scientists reveal strigolactone perception mechanism and role in tillering responses to nitrogen

2024-11-07

“How is plant growth controlled?” and “What is the basis of variation in stress tolerance in plants?” were among the 125 most challenging scientific questions, according to the journal Science in 2016. Strigolactone (SL) is an important plant hormone that plays essential roles in regulating branch number, a key growth and development trait for plants. Recently, scientists from the Chinese Academy of Sciences (CAS) have uncovered the mechanism behind SL perception and its key role in the tillering response to nitrogen. The “gas and brake” mechanism of SL perception allows “smart and flexible” regulation of the duration ...

Increasing trend of overweight and obesity among Japanese patients with incident end-stage kidney disease

2024-11-07

Niigata, Japan - A new nationwide study from Japan spanning a 14 year study period has revealed an increasing trend of overweight and obesity in patients with the incident end-stage kidney disease (ESKD). Although, underweight individuals remain prevalent in this patient population, the study highlights that excessive weight and obesity in patients with the incident ESKD is a shared global challenge. Consequently, the study suggests the need for public health strategies to address the global obesity epidemic as well as underweight individuals in incident ESKD populations. “The global ...

An extra five minutes of exercise per day could help to lower blood pressure

2024-11-07

Adding small amounts of exercise into daily routine, such as climbing stairs or cycling to the shops, could help to reduce blood pressure, with just five additional minutes a day estimated to yield improvements, finds a new study from researchers at UCL and the University of Sydney. The study, supported by the British Heart Foundation (BHF) and published in Circulation, analysed health data from 14,761 volunteers who wore activity trackers to explore the relationship between daily movement and blood pressure. The researchers split daily activity into six behaviours1: Sleep Sedentary behaviour (such as sitting) Slow walking (cadence ...

Mitochondrial dysfunction research transforms mental health: Dr. Ana Andreazza's vision

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: